好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Fluorescein-guided Surgery in Brain Tumors: A Systematic Review and Meta-analysis
Neuro-oncology
P11 - Poster Session 11 (11:45 AM-12:45 PM)
6-006
Fluorescein sodium (FS) has become increasingly popular in neurosurgery as a low-cost intraoperative fluorophore to improve tumor margin visualization and achieve maximum resection (EOR) in the brain tumor resection. Even with its growing adoption, evidence is still mixed on its efficacy, safety and optimal use.
The purpose of this systematic review and meta-analysis was to assess the clinical effectiveness, safety, and utility of SF-guided surgery in brain tumors with emphasis on the resection rates, dosage, the time of administration, and the adverse outcomes.
Using PRISMA and JBI recommendations, PubMed, Scopus, and Google Scholar have been thoroughly searched. Eighty-eight clinical trials, cohort and case series and reports were analysed. Independent reviewers carried out data extraction and critical appraisal, and meta-analysis was done on EOR outcomes.

The results of the resection between 22 clinical trials and cohort studies (2509 SF patients and 2642 controls) reported pooled odds ratio of 1.28 (95% CI: 0.88-1.86) with high heterogeneity. Subtotal resections supported SF (OR: 0.39, 95% CI: 0.25-0.63) whereas, controls led in total resections. General usefulness was 97.3%. Increase in SF doses (10-20mg/kg) caused significant differences in total resection rates (88.2% vs.77.1%, χ²=21.11, p<0.001).

Dural incision timing was found to provide better EOR in comparison to timing at anesthesia induction (86.1% vs. 83.8%, p=0.034). In 5,421 patients, the most frequent use of SFs was in the case of glioblastomas and metastases, where 82.3% of all patients who received an intervention had undergone total resection compared with 72.5% who did not. The number of adverse events was low and mostly mild (93.8%).
Neurosurgery guided by SF improves the visualization and increase the conversion of subtotal to total resection and dose and timing had significant effects. It is safe, can be used in a broad range of tumor types and locations.
Authors/Disclosures
Bashar Abualsebaa, MD
PRESENTER 		Mr. Abualsebaa has nothing to disclose.
Sadeen Eid Sadeen Eid has nothing to disclose.
Yousof Al-Bojoq, Sr., PhD Dr. Al-Bojoq has nothing to disclose.
Amer A. Alomari, MD, MBBS Prof. Alomari has nothing to disclose.
Luciano Mastronardi, MD Dr. Mastronardi has nothing to disclose.
Omar Bushnaq, MD Mr. Bushnaq has nothing to disclose.
Mohammed Alkhateeb, MD Dr. Alkhateeb has nothing to disclose.
Heba A. Aboeqab, MD Dr. Aboeqab has nothing to disclose.
Neveen M. Muqbel, MD Dr. Muqbel has nothing to disclose.
Reem A. Alwahsh, MD Dr. Alwahsh has nothing to disclose.
Bara M. Hammadeh Mr. Hammadeh has nothing to disclose.